journal
Journals Lung Cancer : Journal of the I...

Lung Cancer : Journal of the International Association for the Study of Lung Cancer

https://read.qxmd.com/read/38493759/survival-benefit-in-egfr-wild-and-alk-negative-nsclc-patients-who-participate-in-clinical-trials-compared-to-standard-of-care-propensity-matched-analysis
#1
JOURNAL ARTICLE
Hyun Ae Jung, Boram Park, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
OBJECTIVES: Advanced non-small cell lung cancer patients harboring EGFR mutation or ALK fusion have achieved significant survival benefit with targeted agents. In contrast, EGFR-wild type and ALK negative lung adenocarcinoma still have poor survival outcome. This study assessed the impact of participating in clinical trials on clinical outcomes in patients with EGFR-wild-type and ALK-negative lung adenocarcinoma. MATERIALS AND METHODS: This study included patients with advanced EGFR-wild-type and ALK-negative lung adenocarcinoma who received systemic treatment between March 2017 and June 2022...
March 13, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38489996/comment-on-frozen-sections-accurately-predict-the-iaslc-proposed-grading-system-and-prognosis-in-patients-with-invasive-lung-adenocarcinomas
#2
LETTER
Tianfei Yu, Xue Zhou, Ming Li
No abstract text is available yet for this article.
March 12, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38471416/durvalumab-in-combination-with-chemoradiotherapy-for-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer-results-from-the-phase-1-clover-study
#3
JOURNAL ARTICLE
Dong-Wan Kim, Byoung Chul Cho, Krishna Pachipala, Sang-We Kim, Chih-Liang Wang, Gee-Chen Chang, Myung-Ju Ahn, Rosa Alvarez, Chao-Hua Chiu, José Trigo, Anna Estival, Sana D Karam, Cathy O'Brien, Hema Gowda, Haiyi Jiang, Julie E Bauman
INTRODUCTION: For patients with unresectable, stage III non-small-cell lung cancer (NSCLC), current standard of care is concurrent chemoradiotherapy (cCRT) followed by consolidation durvalumab. However, earlier initiation of durvalumab simultaneously with cCRT may increase antitumor activity relative to initiation after cCRT. The phase 1 CLOVER study (NCT03509012) evaluated durvalumab combined with cCRT in patients with advanced solid tumors; we report findings from the NSCLC cohort. METHODS: CLOVER comprised a dose-limiting toxicity (DLT) assessment part, followed by an expansion part...
March 7, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38461767/population-based-survival-rates-after-curative-surgical-and-non-surgical-treatment-of-stage-iii-nsclc-since-2017
#4
JOURNAL ARTICLE
R A M Damhuis, C Dickhoff, I Bahce, S Senan
OBJECTIVES: In stage III non-small cell lung cancer (NSCLC), curative treatment approaches used to include neoadjuvant therapy followed by surgery, and definitive chemoradiotherapy followed by consolidation durvalumab (CRT-ICI). Surgical strategies included either neoadjuvant chemotherapy (CTx-surg) or chemoradiotherapy (CRT-surg). We studied the outcomes of these three radical intent strategies in the Netherlands Cancer Registry (NCR) for patients diagnosed from 2017 to 2021. MATERIALS AND METHODS: Patients with clinical stage III NSCLC (TNM edition 8) were identified in the NCR after excluding patients with known driver mutations, ECOG performance status >=2, N3-disease and those undergoing sequential chemoradiotherapy or single modality/palliative treatments...
March 7, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38452600/outcomes-of-patients-with-advanced-epithelial-growth-factor-receptor-mutant-lung-cancer-treated-with-first-line-osimertinib-who-would-not-have-met-the-eligibility-criteria-for-the-flaura-clinical-trial
#5
JOURNAL ARTICLE
J Connor Wells, Monica M Mullin, Cheryl Ho, Barbara Melosky, Janessa Laskin, Ying Wang, Sophie Sun
OBJECTIVES: Osimertinib is largely used as first-line therapy for metastatic epithelial growth factor receptor (EGFR) mutant lung cancers based on the FLAURA clinical trial. Real-world patient outcomes often differ from clinical trial outcomes. This study evaluated the efficacy of first-line osimertinib in patients treated in British Columbia (BC), Canada. Furthermore, we compared the outcomes of patients who would and would not have been eligible for the original FLAURA trial. METHODS: Consecutive patients receiving first-line osimertinib for metastatic EGFR exon19 or L858R lung cancer were identified using the BC Cancer Pharmacy Database...
March 4, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38461768/uncommon-de-novo-egfr-t790m-mutant-nsclc-characterized-with-unique-genetic-features-clinical-response-and-acquired-resistance-to-the-third-generation-egfr-tkis-treatment
#6
JOURNAL ARTICLE
Lan-Lan Pang, Wei-Tao Zhuang, Yi-Hua Huang, Jun Liao, Meng-Zhen Li, Yi Lv, Li Zhang, Wen-Feng Fang
INTRODUCTION: The literature on de novo EGFRT790M -mutant patients diagnosed with lung cancer is limited, and there is currently no consensus concerning the most effective treatment protocols. This study aimed to investigate the genomic characteristics of de novoEGFRT790M -mutant non-small cell lung cancer (NSCLC) and provide insights into its clinical response and resistance mechanism to third-generation EGFR-TKIs. METHODS: Next-generation sequencing was utilized to screen a substantial cohort of 4,228 treatment-naïve patients from the Mygene genomic database to identifythe de novo EGFR-T790M mutation...
March 2, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38452601/association-of-patient-and-health-care-organization-factors-with-incidental-nodule-guidelines-adherence-a-multi-system-observational-study
#7
JOURNAL ARTICLE
Christopher G Slatore, Elizabeth R Hooker, Sarah Shull, Sara E Golden, Anne C Melzer
BACKGROUND: Health care organizations are increasingly developing systems to ensure patients with pulmonary nodules receive guideline-adherent care. Our goal was to determine patient and organization factors that are associated with radiologist adherence as well as clinician and patient concordance to 2005 Fleischner Society guidelines for incidental pulmonary nodule follow-up. MATERIALS: Trained researchers abstracted data from the electronic health record from two Veterans Affairs health care systems for patients with incidental pulmonary nodules as identified by interpreting radiologists from 2008 to 2016...
February 29, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38432027/describing-differences-among-populations-of-thoracic-tumors-patients-under-and-over-80%C3%A2-years-data-analysis-from-the-slcg-thoracic-tumor-registry
#8
JOURNAL ARTICLE
Mariano Provencio, Manuel Cobo, Delvys Rodriguez-Abreu, Enric Carcereny, Alexandra Cantero, Virginia Calvo, Rafael López Castro, Reyes Bernabé, Joaquim Bosch-Barrera, Bartomeu Massutí, Rosario García Campelo, Alfredo Sánchez-Hernández, Ana Laura Ortega, Maria Guirado, Edel Del Barco, Carlos Camps, Joaquin Casal-Rubio, Manuel Dómine, Mª Angeles Sala, Airam Padilla, Jose Luís González Larriba, Francisco de Asís Aparisi
OBJECTIVES: Cancer is a disease of old age; however, most studies usually included minority of patients fit elderly. The purpose is to investigate the clinical characteristics and genetic information of patients with thoracic tumors who are 80 years old or older compared to those under 80 years old. STUDY DESIGN AND METHODS: The Thoracic Tumor Registry (TTR) is a Spanish observational, prospective cohort study that included patients diagnosed with thoracic tumors...
February 29, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38432026/the-danish-lung-cancer-registry-a-nationwide-validation-study
#9
JOURNAL ARTICLE
Anja Gouliaev, Fatima Ali, Erik Jakobsen, Susanne O Dalton, Ole Hilberg, Torben R Rasmussen, Niels L Christensen
BACKGROUND: This study evaluates the validity of the information in the Danish Lung Cancer Registry (DLCR). Since 2000, the DLCR has been a tool for monitoring interventions and outcome of all Danish lung cancer patients with the intent to streamline and improve treatment and survival. The DLCR receives information from the Danish Patient Registries in addition to clinical information from the treating physicians. In the year 2022, more than 50 papers have been published using DLCR as a data source...
February 29, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38447302/lung-cancer-detection-in-perioperative-patients-exhaled-breath-with-nanomechanical-sensor-array
#10
JOURNAL ARTICLE
Yusuke Saeki, Naoki Maki, Takahiro Nemoto, Katsushige Inada, Kosuke Minami, Ryo Tamura, Gaku Imamura, Yukiko Cho-Isoda, Shinsuke Kitazawa, Hiroshi Kojima, Genki Yoshikawa, Yukio Sato
INTRODUCTION: Breath analysis using a chemical sensor array combined with machine learning algorithms may be applicable for detecting and screening lung cancer. In this study, we examined whether perioperative breath analysis can predict the presence of lung cancer using a Membrane-type Surface stress Sensor (MSS) array and machine learning. METHODS: Patients who underwent lung cancer surgery at an academic medical center, Japan, between November 2018 and November 2019 were included...
February 25, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38417278/association-between-surgical-quality-and-long-term-survival-in-lung-cancer
#11
JOURNAL ARTICLE
James D Lee, Richard Zheng, Olugbenga T Okusanya, Nathaniel R Evans, Tyler R Grenda
OBJECTIVES: There are significant variations in both perioperative and long-term outcomes after lung cancer resection. While perioperative outcomes are often used as comparative measures of quality, they are unreliable, and their association with long-term outcomes remain unclear. In this context, we evaluated whether historical perioperative mortality after lung cancer resection is associated with 5-year survival. PATIENTS AND METHODS: The National Cancer Database (NCDB) was queried to identify patients diagnosed with non-small cell lung cancer (NSCLC) in 2010-2016 who underwent surgical resection (n = 234200)...
February 25, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38432028/outcomes-in-patients-treated-with-frontline-immune-checkpoint-inhibition-ici-for-advanced-nsclc-with-kras-mutations-and-stk11-keap1-comutations-across-pd-l1-levels
#12
JOURNAL ARTICLE
Lova Sun, Elizabeth A Handorf, Yunyun Zhou, Hossein Borghaei, Charu Aggarwal, Jessica Bauman
INTRODUCTION: In patients with advanced NSCLC (aNSCLC), the impact of KRAS mutations (m) and comutations with STK11 and KEAP1 on outcomes across different PD-L1 levels remains incompletely understood. We aimed to investigate the frequency of KRAS mutations and comutations across PD-L1 levels, and the association between these mutations and survival, stratified by PD-L1 expression. METHODS: We conducted a nationwide cohort study of patients diagnosed with aNSCLC between 2016 and 2021 treated with frontline (chemo)immunotherapy, who underwent molecular genotyping including KRAS, STK11, and KEAP1...
February 24, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38417277/phase-ii-study-investigating-the-efficacy-and-safety-of-glesatinib-mgcd265-in-patients-with-advanced-nsclc-containing-met-activating-alterations
#13
JOURNAL ARTICLE
David S Hong, Federico Cappuzzo, Byoung Chul Cho, Afshin Dowlati, Maen Hussein, Dong-Wan Kim, Ivor Percent, James G Christensen, Josée Morin, Diane Potvin, Demiana Faltaos, Vanessa Tassell, Hirak Der-Torossian, Richard Chao
OBJECTIVES: Dysregulated signaling by mesenchymal epithelial transition factor (MET) and heightened AXL activation are implicated in the pathogenesis of non-small cell lung cancer (NSCLC). Glesatinib (MGCD265) is an investigational, oral inhibitor of MET and AXL. MATERIALS AND METHODS: This open-label, Phase II study investigated glesatinib (free-base suspension [FBS] capsule 1050 mg BID or spray-dried dispersion [SDD] tablet 750 mg BID) in patients with advanced, previously treated NSCLC across four cohorts grouped according to presence of MET activating mutations or amplification in tumor or ctDNA...
February 22, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38432025/lazertinib-as-a-frontline-treatment-in-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer-long-term-follow-up-results-from-laser201
#14
JOURNAL ARTICLE
Byoung Chul Cho, Ji-Youn Han, Ki Hyeong Lee, Yun-Gyoo Lee, Dong-Wan Kim, Young Joo Min, Sang-We Kim, Eun Kyung Cho, Joo-Hang Kim, Gyeong-Won Lee, Sung Sook Lee, NaMi Lee, Jang Young Wang, Hyejoo Park, Myung-Ju Ahn
OBJECTIVE: This analysis of the first-line cohort of LASER201 study evaluated the efficacy and safety of lazertinib 240 mg as a frontline therapy for epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). METHODS: A total of 43 patients, with EGFR mutation-positive (Exon19Del, n = 24; L858R, n = 18; G719X, n = 1) locally advanced or metastatic NSCLC who had not previously received EGFR tyrosine kinase inhibitor (EGFR TKI) therapy, received once-daily lazertinib 240 mg...
February 20, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38428265/stk11-lkb1-alterations-worsen-the-poor-prognosis-of-kras-mutated-early-stage-non-squamous-non-small-cell-lung-carcinoma-results-based-on-the-phase-2-ifct-taste-trial
#15
JOURNAL ARTICLE
Jean Baptiste Oudart, Simon Garinet, Caroline Leger, Fabrice Barlesi, Julien Mazières, Gaelle Jeannin, Clarisse Audigier-Valette, Denis Morot-Sibilot, Alexandra Langlais, Elodie Amour, Nathalie Mathiot, Gary Birsen, Hélène Blons, Marie Wislez
BACKGROUND: STK11/LKB1 mutations have been associated with primary resistance to PD-1 axis inhibitors and poor prognosis in advanced KRAS-mutant lung adenocarcinoma. This study aimed to assess the prognostic significance of STK11/LKB1 alterations in localized non-squamous non-small cell lung carcinoma (non-sq NSCLC). PATIENTS AND METHODS: Surgical samples from patients undergoing complete resection for stage IIa, IIb, or IIIa (N2 excluded) non-sq NSCLC in the randomized adjuvant phase II trial (NCT00775385 IFCT-1801 TASTE trial) were examined...
February 19, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38422883/blood-tumor-mutational-burden-and-response-to-pembrolizumab-plus-chemotherapy-in-non-small-cell-lung-cancer-keynote-782
#16
JOURNAL ARTICLE
Jair Bar, Emilio Esteban, Delvys Rodríguez-Abreu, Santiago Ponce Aix, Zsuzsanna Szalai, Enriqueta Felip, Maya Gottfried, Mariano Provencio, Andrew Robinson, Andrea Fülöp, Suman Bannur Rao, D Ross Camidge, Giovanna Speranza, Steven M Townson, Julie Kobie, Mark Ayers, E J Dettman, Nathan Hunkapiller, Robert McDaniel, Byoungsok Jung, David Burkhardt, Ruth Mauntz, Tibor Csőszi
BACKGROUND: First-line pembrolizumab plus chemotherapy has shown clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC) regardless of tissue tumor mutational burden (tTMB) status. Blood tumor mutational burden (bTMB), assessed using plasma-derived circulating tumor DNA (ctDNA), may be a surrogate for tTMB. The KEYNOTE-782 study evaluated the correlation of bTMB with the efficacy of first-line pembrolizumab plus chemotherapy in NSCLC. METHODS: Previously untreated patients with stage IV nonsquamous NSCLC received pembrolizumab 200 mg plus pemetrexed 500 mg/m2 and investigator's choice of carboplatin area under the curve 5 mg/mL/min or cisplatin 75 mg/m2 for 4 cycles, then pembrolizumab plus pemetrexed for ≤31 additional cycles every 3 weeks...
February 17, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38394745/dosiomics-and-radiomics-based-prediction-of-pneumonitis-after-radiotherapy-and-immune-checkpoint-inhibition-the-relevance-of-fractionation
#17
JOURNAL ARTICLE
Kim Melanie Kraus, Maksym Oreshko, Julia Anne Schnabel, Denise Bernhardt, Stephanie Elisabeth Combs, Jan Caspar Peeken
OBJECTIVES: Post-therapy pneumonitis (PTP) is a relevant side effect of thoracic radiotherapy and immunotherapy with checkpoint inhibitors (ICI). The influence of the combination of both, including dose fractionation schemes on PTP development is still unclear. This study aims to improve the PTP risk estimation after radio(chemo)therapy (R(C)T) for lung cancer with and without ICI by investigation of the impact of dose fractionation on machine learning (ML)-based prediction. MATERIALS AND METHODS: Data from 100 patients who received fractionated R(C)T were collected...
February 17, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38367405/integration-of-on-treatment-modified-glasgow-prognostic-score-mgps-to-improve-imaging-based-prediction-of-outcomes-in-patients-with-non-small-cell-lung-cancer-on-immune-checkpoint-inhibition
#18
JOURNAL ARTICLE
Jonas Saal, Tobias Bald, Markus Eckstein, Damian J Ralser, Peter Brossart, Jörg Ellinger, Michael Hölzel, Niklas Klümper
INTRODUCTION: A large number of patients with non-small cell lung cancer (NSCLC) on immune checkpoint inhibition (ICI) achieve stable disease (SD) as the best overall response, which is associated with heterogeneous outcomes. In this context, complementary biomarkers that improve outcome prediction are needed. We have recently demonstrated that measuring the on-treatment modified Glasgow prognostic score (mGPS), which is based on the two serum markers C-reactive protein (CRP) and albumin, can improve outcome prediction complementary to radiological staging in metastatic renal cell carcinoma...
February 15, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38359741/longitudinal-plasma-proteomic-profiling-of-eml4-alk-positive-lung-cancer-receiving-alk-tkis-therapy
#19
JOURNAL ARTICLE
Shasha Wang, Xuezhi Hao, Liyuan Dai, Ning Lou, Guangyu Fan, Ruyun Gao, Mengwei Yang, Puyuan Xing, Yutao Liu, Lin Wang, Zhishang Zhang, Jiarui Yao, Le Tang, Yuankai Shi, Xiaohong Han
BACKGROUND: Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) has demonstrated remarkable therapeutic effects in ALK-positive non-small cell lung cancer (NSCLC) patients. Identifying prognostic biomarkers can enhance the clinical efficacy of relapsed or refractory patients. METHODS: We profiled 737 plasma proteins from 159 pre-treatment and on-treatment plasma samples of 63 ALK-positive NSCLC patients using data-independent acquisition-mass spectrometry (DIA-MS)...
February 9, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38342048/drastic-response-of-sunitinib-after-failure-of-lenvatinib-in-patients-with-previously-treated-thymic-carcinoma
#20
LETTER
Kyoichi Kaira, Hisao Imai, Hiroshi Kagamu
No abstract text is available yet for this article.
February 9, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.